All data are based on the daily closing price as of January 20, 2026
h
Hisamitsu Pharmaceutical
4530.TSE
40.62 USD
0.46
+1.15%
Overview
Last close
40.62 usd
Market cap
2.86B usd
52 week high
41.11 usd
52 week low
25.59 usd
Target price
27.42 usd
Valuation
P/E
15.6542
Forward P/E
N/A
Price/Sales
2.8139
Price/Book Value
1.6532
Enterprise Value
2.13B usd
EV/Revenue
2.1615
EV/EBITDA
10.3479
Key financials
Revenue TTM
985.69M usd
Gross Profit TTM
588.77M usd
EBITDA TTM
157.60M usd
Earnings per Share
1.71 usd
Dividend
0.56 usd
Total assets
2.19B usd
Net debt
-634.59M usd
About
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as, external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asia, the United States, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.